As of November 10, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Shattuck Labs, Inc. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 15.3%. 14 filings are on record since July 16, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Shattuck Labs, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 5,221,737 · Shared voting: 0 · Sole dispositive: 5,339,458 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 13,391,090 · Shared voting: 0 · Sole dispositive: 13,432,540 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Redmile Group, LLC · Sole voting: 0 · Shared voting: 10,019,421 · Sole dispositive: 0 · Shared dispositive: 10,019,421 · SCHEDULE 13D/A, 2026-07-17
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 5,000,033 · Sole dispositive: 0 · Shared dispositive: 5,000,033 · SCHEDULE 13G, 2026-06-17
- · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 9,021,127 · Sole dispositive: 0 · Shared dispositive: 9,021,127 · SCHEDULE 13D/A, 2026-06-15
Shattuck Labs, Inc. has 14 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 15.3% | 13,432,540 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Orbimed Advisors LLC | 9.99% | 9,021,127 | SCHEDULE 13D/A, 2026-06-15 | 2026-06-11 |
| Redmile Group, LLC | 9.9% | 10,019,421 | SCHEDULE 13D/A, 2026-07-17 | 2026-07-15 |
| Prosight Management, LP | 9.9% | 6,543,240 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| BlackRock, Inc. | 5.3% | 5,339,458 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Deep Track Capital, LP | 5.17% | 5,000,033 | SCHEDULE 13G, 2026-06-17 | 2026-06-10 |
| The Vanguard Group | 4.48% | 2,148,174 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
Holding shares or following this stake? See who's behind Shattuck Labs, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Shattuck Labs, Inc. and the records around it.
Shattuck Labs, Inc. elsewhere on the record
Companies that share a holder
- Prosight Management, LP also filed stake reports on 5 other companies: OnKure Therapeutics, Inc. (Aug 2026), ADC Therapeutics SA (Feb 2026), MeiraGTx Holdings plc (Feb 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Shattuck Labs, Inc.
Get an email when Shattuck Labs, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Shattuck Labs, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Shattuck Labs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Shattuck Labs, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13,391,090 | 0 | 13,432,540 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Orbimed Advisors LLC | 0 | 9,021,127 | 0 | 9,021,127 | SCHEDULE 13D/A, 2026-06-15 |
| OrbiMed Capital GP IX LLC | 0 | 7,517,606 | 0 | 7,517,606 | SCHEDULE 13D/A, 2026-06-15 |
| OrbiMed Genesis GP LLC | 0 | 1,503,521 | 0 | 1,503,521 | SCHEDULE 13D/A, 2026-06-15 |
| Redmile Group, LLC | 0 | 10,019,421 | 0 | 10,019,421 | SCHEDULE 13D/A, 2026-07-17 |
| Jeremy C. Green | 0 | 10,019,421 | 0 | 10,019,421 | SCHEDULE 13D/A, 2026-07-17 |
| Redmile Biopharma Investments II, L.P. | 0 | 8,125,342 | 0 | 8,125,342 | SCHEDULE 13D/A, 2026-07-17 |
| BlackRock, Inc. | 5,221,737 | 0 | 5,339,458 | 0 | SCHEDULE 13G, 2026-10-27 |
| Deep Track Capital, LP | 0 | 5,000,033 | 0 | 5,000,033 | SCHEDULE 13G, 2026-06-17 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 5,000,033 | 0 | 5,000,033 | SCHEDULE 13G, 2026-06-17 |
| David Kroin | 0 | 5,000,033 | 0 | 5,000,033 | SCHEDULE 13G, 2026-06-17 |
The latest filing identifies Shattuck Labs, Inc. by CUSIP 82024L103 and gives its principal executive office as 500 W. 5th Street, Suite 1200, AUSTIN, TX 78701 (SCHEDULE 13G, 2026-10-27).
Source of funds (Item 3)
On August 4, 2025, the Issuer entered into a securities purchase agreement with certain institutional accredited investors ("PIPE Investors"), pursuant to which, the Issuer agreed to issue and sell to the PIPE Investors in a private placement an aggregate of 15,225,158 Shares and, to certain PIPE Investors, pre-funded warrants (the "2025 Pre-Funded Warrants") to purchase up to an aggregate of 37,410,188 Shares and, in each case, accompanying warrants (the "2025 Common Warrants") to purchase up to an aggregate of 52,635,346 Shares, or in lieu thereof, 2025 Pre-Funded Warrants (the "PIPE").Orbimed Advisors LLC, SCHEDULE 13D/A, 2026-06-15
Item 3 of the Prior Schedule 13D is hereby amended and supplemented in its entirety by adding the following paragraphs after the last paragraph of Item 3: On July 17, 2026, certain private investment funds managed by Redmile (the "Redmile Funds"), not including RBI II, utilized their working capital in an aggregate amount of approximately $1,000,000 to acquire 143,808 shares of the Issuer's Common Stock. The participating Redmile Funds purchased the shares in open market transactions at a price of approximately $7.46 per share.Redmile Group, LLC, SCHEDULE 13D/A, 2026-07-17
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 1.8% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 4.48% | SCHEDULE 13G/A |
| 2025-08-06 | Redmile Group, LLC | 11.8% | SCHEDULE 13D/A |
| 2025-08-26 | Redmile Group, LLC | 9.9% | SCHEDULE 13D/A |
| 2025-09-02 | Orbimed Advisors LLC | 9.99% | SCHEDULE 13D |
| 2025-11-13 | Prosight Management, LP | 9.9% | SCHEDULE 13G/A |
| 2026-02-06 | T. Rowe Price Investment Management, Inc. | 11.7% | SCHEDULE 13G |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 13.8% | SCHEDULE 13G/A |
| 2026-06-11 | Redmile Group, LLC | 9.9% | SCHEDULE 13D/A |
| 2026-06-15 | Orbimed Advisors LLC | 9.99% | SCHEDULE 13D/A |
| 2026-06-17 | Deep Track Capital, LP | 5.17% | SCHEDULE 13G |
| 2026-07-17 | Redmile Group, LLC | 9.9% | SCHEDULE 13D/A |
| 2026-08-14 | T. Rowe Price Investment Management, Inc. | 15.3% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 5.3% | SCHEDULE 13G |
Questions about who owns Shattuck Labs, Inc.
Who owns Shattuck Labs, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Shattuck Labs, Inc.: T. Rowe Price Investment Management, Inc. (15.3%, Schedule 13G/A, filed 2026-08-14), Orbimed Advisors LLC (9.99%, Schedule 13D/A, filed 2026-06-15), Redmile Group, LLC (9.9%, Schedule 13D/A, filed 2026-07-17), Prosight Management, LP (9.9%, Schedule 13G/A, filed 2025-11-13) and BlackRock, Inc. (5.3%, Schedule 13G, filed 2026-10-27); 1 more is listed above.
Who are the largest shareholders of Shattuck Labs, Inc.?
By the share each holder's latest filing reports, the largest holders of Shattuck Labs, Inc. on this page are T. Rowe Price Investment Management, Inc. (15.3%), Orbimed Advisors LLC (9.99%) and Redmile Group, LLC (9.9%).
When did T. Rowe Price Investment Management, Inc. buy into Shattuck Labs, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G, filed 2026-02-06, reporting 11.7%; its latest, Schedule 13G/A filed 2026-08-14, reports 15.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Shattuck Labs, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Shattuck Labs, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.